Figure 2 Pharmacokinetic action profiles of rapid-acting insulins

Slides:

Advertisements

Similar presentations

Insulin therapy.

Advertisements

Insulin Type (trade name)

Key publication slides

Representative insulin regimens for the treatment of diabetes

Key publication slides

Representative insulin regimens for the treatment of diabetes

Representative insulin regimens for the treatment of diabetes

Nat. Rev. Endocrinol. doi: /nrendo

Representative insulin regimens for the treatment of diabetes

Key publication slides

Representative insulin regimens for the treatment of diabetes

Figure 3 Childhood craniopharyngioma

Figure 1 Framework for variant interpretation of phaeochromocytomas and/or paragangliomas (PPGLs) susceptibility genes into five classes based on the likelihood.

Figure 2 Pathophysiology of hyperglycaemia in T2DM

Faster-Acting Insulins

T1DM: Insulin Initiation

with undiagnosed diabetes mellitus by three diagnostic criteria

Technosphere® Inhaled Human Insulin has a More Rapid Onset of Action Than Subcutaneous Insulins - Meta Analysis of Clamp data From Three Clinical Studies.

Figure 4 Amino acid structure of short-acting and long-acting insulins

Nat. Rev. Endocrinol. doi: /nrendo

Figure 5 Schematic illustration of different clinical trial designs

Figure 1 Mendelian randomization study

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Monogenic forms of diabetes mellitus

Figure 5 MRI of childhood craniopharyngioma

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Bimodal distribution of the glutamic acid decarboxylase

Nat. Rev. Endocrinol. doi: /nrendo

Figure 2 Circadian and ultradian fluctuations in corticosterone

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo

Figure 1 Intensity-based loading options to increase bone strength

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo

Figure 4 Effects of irisin on glucose homeostasis

Nat. Rev. Endocrinol. doi: /nrendo

Figure 1 Osteosarcoma epidemiology

Figure 1 Challenges and opportunities of using omics in EDC research

Figure 1 Oestrogen biosynthesis and production sites in the body

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo

Figure 4 Tracheal endoscopy in two patients

Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Nat. Rev. Endocrinol. doi: /nrendo

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo

Figure 1 Regulation of hepatic glucose metabolism by the gut, brain and liver Figure 1 | Regulation of hepatic glucose metabolism by the gut, brain and.

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo

Figure 3 Pharmacodynamic action profiles of long-acting insulins

Nat. Rev. Endocrinol. doi: /nrendo

Figure 1 Sites of action of glucose-lowering agents

Figure 2 Gut microbial gene content and development of T1DM

Nat. Rev. Cardiol. doi: /nrcardio

Evolution of Insulin: From Human to Analog

Figure 1 Timeline of pancreatic islet transplantation

Nat. Rev. Endocrinol. doi: /nrendo

Figure 1 Exercise enhances insulin sensitivity

Figure 3 Global iodine status and mandatory salt iodization

Case report: male 63 years old with documented stenosis of the internal cerebral artery, diabetes duration 12 years, and treatment with 22 IU insulin glargine.

Nat. Rev. Endocrinol. doi: /nrendo

An insulin simplification regimen: from multiple injections to once-daily long-acting (basal) insulin plus noninsulin agents. *Basal insulins: glargine.

A: Detection of insulin aspart and insulin lispro by the Iso-insulin ELISA method. A: Detection of insulin aspart and insulin lispro by the Iso-insulin.

The ADA research program supports research across the broad spectrum of diabetes types and research topic areas (proportions of 2011 allocations in dollars).

Presentation transcript:

Figure 2 Pharmacokinetic action profiles of rapid-acting insulins Figure 2 | Pharmacokinetic action profiles of rapid-acting insulins. The schematic shows the pharmacokinetic action profiles of rapid-acting insulins7,102. Compared with human regular insulin, insulin aspart, insulin lispro and insulin glulisine have a faster onset of action, a higher peak level and a shorter duration of action. Compared with the other rapid-acting insulin analogues, the curve for rapid-acting insulin aspart is shifted to the left, with a similar area under the curve, but a faster onset and earlier peak. Care must be taken when interpreting the curves, as experimental settings in which the data were gathered differed between studies. IU, international units. Mathieu, C. et al. (2017) Insulin analogues in type 1 diabetes mellitus: getting better all the time Nat. Rev. Endocrinol. doi:10.1038/nrendo.2017.39